Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium

Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean Michael McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. Fernandez Turizo, Caroline T MacVicar, Aditya Ramesh Garg, Alexander Disciullo, Kusha Chopra, Alexandra W. Lenart, Emmanuel Nwodo, Jeffrey A. Barnes, Min Ji Koh, Eliana C M Miranda, Carlos Sergio Chiattone, Robert N Stuver, Steven M Horwitz, Mwanasha H Merrill, Eric D. Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Dr., Sridhar Epari, Alok Shetty, Saswata Saha, Hasmukh Jain, Dr., Manju Sengar, MD, DM, Carrie Van Der Weyden, H Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M Foss, Marianna Gentilini, Beatrice casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al-Mansour, Josie Ford, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Maulik Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood Adv bloodadvances.2024014674.

https://doi.org/10.1182/bloodadvances.2024014674

Published: 2024

Includes: Supplemental data

Journal Articles

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Blood Adv (2024) 8 (18): 4866–4876.

https://doi.org/10.1182/bloodadvances.2024013236

Published: 2024

Includes: Supplemental data

Journal Articles

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

Julia Driessen, Fer de Wit, Alex F. Herrera, Pier Luigi Zinzani, Ann S. LaCasce, Peter D. Cole, Craig H. Moskowitz, Ramón García-Sanz, Michael Fuchs, Horst Müller, Peter Borchmann, Armando Santoro, Heiko Schöder, Josée M. Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten

Blood Adv (2024) 8 (11): 2740–2752.

https://doi.org/10.1182/bloodadvances.2023012145

Published: 2024

Includes: Supplemental data

Journal Articles

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Blood Adv (2024) 8 (10): 2400–2404.

https://doi.org/10.1182/bloodadvances.2023011030

Published: 2024

Includes: Supplemental data

Journal Articles

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Tycel J. Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Ping Jiang, Peter Johnson

Blood Adv (2024) 8 (4): 867–877.

https://doi.org/10.1182/bloodadvances.2023010648

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, Laura Liao, Lei Chen, John Radford, Weiyun Ai, Melhem Solh, Kirit M. Ardeshna, Brian Hess, Paolo F. Caimi, Anastasios Stathis, Carmelo Carlo-Stella, Juan Pablo Alderuccio, Brad Kahl, Ying Wang, Yajuan Qin, Zhiying Cindy Xu, Pier Luigi Zinzani

Blood Adv (2023) 8 (1): 93–98.

https://doi.org/10.1182/bloodadvances.2023010636

Published: 2023

Includes: Supplemental data

Journal Articles

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Blood Adv (2023) 7 (22): 6801–6811.

https://doi.org/10.1182/bloodadvances.2023010668

Published: 2023

Includes: Supplemental data

Journal Articles

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Alessandro Broccoli, Lisa Argnani, Laura Nanni, Vittorio Stefoni, Cinzia Pellegrini, Beatrice Casadei, Gabriele Gugliotta, Matteo Carella, Paolo Elia Coppola, Gianmarco Bagnato, Pier Luigi Zinzani

Blood Adv (2023) 7 (21): 6762–6766.

https://doi.org/10.1182/bloodadvances.2023010742

Published: 2023

Includes: Supplemental data

Journal Articles

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Blood Adv (2023) 7 (20): 6266–6274.

https://doi.org/10.1182/bloodadvances.2023010334

Published: 2023

Includes: Supplemental data

Journal Articles

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz

Blood Adv (2023) 7 (18): 5272–5280.

https://doi.org/10.1182/bloodadvances.2023010254

Published: 2023

Includes: Supplemental data

Journal Articles

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Blood Adv (2023) 7 (16): 4435–4447.

https://doi.org/10.1182/bloodadvances.2022009575

Published: 2023

Includes: Supplemental data

Journal Articles

Role of stem cell transplant in CD30 + PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Blood Adv (2022) 6 (19): 5550–5555.

https://doi.org/10.1182/bloodadvances.2020003971

Published: 2022

Includes: Supplemental data

Journal Articles

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Alessandro Broccoli, Lisa Argnani, Matthew Cross, Agnieszka Janus, Elsa Maitre, Xavier Troussard, Tadeusz Robak, Claire Dearden, Monica Else, Daniel Catovsky, Pier Luigi Zinzani

Blood Adv (2022) 6 (14): 4224–4227.

https://doi.org/10.1182/bloodadvances.2022007854

Published: 2022

Includes: Supplemental data

Journal Articles

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Blood Adv (2022) 6 (12): 3606–3610.

https://doi.org/10.1182/bloodadvances.2021006922

Published: 2022

Includes: Supplemental data

Journal Articles

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Blood Adv (2022) 6 (7): 2035–2044.

https://doi.org/10.1182/bloodadvances.2021006844

Published: 2022

Journal Articles

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Jose S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhit Özcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla

Blood Adv (2022) 6 (2): 590–599.

https://doi.org/10.1182/bloodadvances.2021004970

Published: 2022

Includes: Supplemental data

Journal Articles

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Blood Adv (2021) 5 (23): 5332–5343.

https://doi.org/10.1182/bloodadvances.2021005132

Published: 2021

Includes: Supplemental data

Journal Articles

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

Blood Adv (2021) 5 (23): 5098–5106.

https://doi.org/10.1182/bloodadvances.2021004710

Published: 2021

Includes: Supplemental data

Journal Articles

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial

Blood Adv (2021) 5 (21): 4504–4514.

https://doi.org/10.1182/bloodadvances.2021005150

Published: 2021

Includes: Supplemental data

Journal Articles

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial

Alex F. Herrera, Catherine Burton, John Radford, Fiona Miall, William Townsend, Armando Santoro, Pier Luigi Zinzani, David Lewis, Camilla Fowst, Satjit Brar, Bo Huang, Aron Thall, Graham P. Collins

Blood Adv (2021) 5 (17): 3387–3396.

https://doi.org/10.1182/bloodadvances.2021004511

Published: 2021

Includes: Supplemental data

NARROW

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Role of stem cell transplant in CD30 + PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only